Twitter is a global platform that connects a user to a network of people, news, ideas, opinions and information. A user can tweet his/her take on any subject in real time, which can be retweeted by others. Tweets are limited to 280 characters.
Twitter uses an asymmetric follow model, which means that the relationships between users may not be reciprocal. The company enables users to search and discover content in which they are interested including tweets that may have attachments like links, media, photos and other applications.
Currently, Twitter has 336 Monthly Active Users (MAUs). Twitter is available on desktop (both Macintosh and PC) and across a wide range of mobile devices including Android, iOS and Blackberry. Additionally, tweets will now be indexed in Google search results as per a deal between the two entities.
Zacks Rank: Currently, Twitter has a Zacks Rank #1 (Strong Buy) but that could change following its second-quarter 2018 earnings report which has just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
We have highlighted some of the key details from the just-released announcement below:
Earnings: Twitter’s adjusted earnings came in at 17 cents per share, which was in line with the Zacks Consensus Estimate.
Revenues: Revenues of $711 million beat the Zacks Consensus Estimate of $700 million and grew 24% on a year-over-year basis.
Key Stats: Average daily active users (DAUs) increased 11% year over year, as compared with 10% year over year growth in the previous quarter.
Stock Price: Shares were down 12.55% in the pre-market trading session.
Check back later for our full write up on this Twitter earnings report later!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Image: Bigstock
Twitter (TWTR) Q2 Earnings In Line, Revenues Surge Y/Y
Twitter is a global platform that connects a user to a network of people, news, ideas, opinions and information. A user can tweet his/her take on any subject in real time, which can be retweeted by others. Tweets are limited to 280 characters.
Twitter uses an asymmetric follow model, which means that the relationships between users may not be reciprocal. The company enables users to search and discover content in which they are interested including tweets that may have attachments like links, media, photos and other applications.
Currently, Twitter has 336 Monthly Active Users (MAUs). Twitter is available on desktop (both Macintosh and PC) and across a wide range of mobile devices including Android, iOS and Blackberry. Additionally, tweets will now be indexed in Google search results as per a deal between the two entities.
Zacks Rank: Currently, Twitter has a Zacks Rank #1 (Strong Buy) but that could change following its second-quarter 2018 earnings report which has just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
We have highlighted some of the key details from the just-released announcement below:
Earnings: Twitter’s adjusted earnings came in at 17 cents per share, which was in line with the Zacks Consensus Estimate.
Revenues: Revenues of $711 million beat the Zacks Consensus Estimate of $700 million and grew 24% on a year-over-year basis.
Key Stats: Average daily active users (DAUs) increased 11% year over year, as compared with 10% year over year growth in the previous quarter.
Stock Price: Shares were down 12.55% in the pre-market trading session.
Twitter, Inc. Price
Twitter, Inc. Price | Twitter, Inc. Quote
Check back later for our full write up on this Twitter earnings report later!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>